The incremental prognostic and clinical value of multiple novel biomarkers in heart failure por Preiss, D

Statin safety and associated adverse events: a scientific statement from the American Heart Association por Preiss, D

Uniformly distributed measures in Euclidean spaces por Kirchheim, B, Preiss, D

Screening for diabetes in patients with cardiovascular disease: HbA1c trumps oral glucose tolerance testing por Preiss, D, Sattar, N

HARMONY or discord in cardiovascular outcome trials of GLP-1 receptor agonists? por Mafham, M, Preiss, D

Cardiovascular disease: PCSK9 inhibition: a new player in cholesterol-lowering therapies? por Preiss, D, Baigent, C

PCSK9 inhibition: the dawn of a new age in cholesterol lowering? por Preiss, D, Mafham, M

Reverse causality in cardiovascular epidemiological research. More common than imagined? por Sattar, N, Preiss, D

Research digest: CV trials in diabetes — Looking ahead por Preiss, D, Sattar, N

Genetic insights into statin-associated diabetes risk por Swerdlow, DI, Preiss, D

Diabetic microvascular complications as simple indicators of risk for cardiovascular outcomes and heart failure por Preiss, D, Sattar, N

Individual participant data meta-analysis of new-onset and worsening diabetes mellitus in large-scale randomized double-blind trials of statin therapy por Preiss, D, Reith, C

Now is good, earlier is better. por Tobert, J, Preiss, D

Tightening our understanding of intensive glycaemic control por Herrington, W, Preiss, D

Efficacy and tolerability of evolocumab vs ezetimibe in patients with muscle-related statin intolerance: the GAUSS-3 randomized clinical trial por Preiss, D, GAUSS-3 Investigators

Cholesteryl ester transfer protein inhibition for preventing cardiovascular events: JACC review topic of the week por Armitage, J, Holmes, M, Preiss, D

Metformin therapy and circulating NT-proBNP levels: the CAMERA trial por Preiss, D, Welsh, P, Sattar, N

Empagliflozin and cardiovascular outcomes in patients with chronic kidney disease: the EMPA-KIDNEY trial por Preiss, D, Herrington, W, Haynes, R

Lipid-modifying agents, from statins to PCSK9 inhibitors: JACC focus seminar por Preiss, D, Tobert, JA, Hovingh, GK, Reith, C

Lipid-modifying agents, from statins to PCSK9 inhibitors por Preiss, D, Tobert, J, Hovingh, G, Reith, C